BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership ...
Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily teriparatide followed by one subcutaneous injection of denosumab experienced a moderate gain in ...
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and ...
On Jan. 5, 2018, the U.S. Food and Drug Administration approved the supplemental Biologics License Application for XGEVA to expand the currently approved indication for the prevention of ...
THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO ® (CT-P41, denosumab-bmwo) and OSENVELT ® (CT-P41, ...
THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA ...
20d
mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
Abxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: AMRX), today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback